Introduction {#Sec1}
============

Currently, cardiovascular diseases remain the leading causes of morbidity and mortality in the developed world \[[@CR1]\]. Despite progress in medical treatment to control cardiovascular risk factors and stabilize the atheromatous plaque, a large number of patients still require myocardial revascularization procedures, with a major shift over the last two decades from coronary artery bypass graft surgery (CABGS) to percutaneous angioplasty intervention (PCI) as the revascularization of choice \[[@CR2], [@CR3]\]. Importantly, the proportion of high-risk patients undergoing CABGS has increased owing to the ageing population and the rising prevalence of associated comorbidities such as diabetes mellitus and heart failure \[[@CR2], [@CR4]\].

On-pump cardiac surgery is associated with predictable myocardial ischaemia--reperfusion damages that parallel the duration of aortic cross-clamping and are greater in the higher risk surgical population presenting with left ventricular hypertrophy, endothelial dysfunction and severe coronary artery disease \[[@CR5]\]. The consequent post-cardiotomy ventricular dysfunction often requires temporary inotropic support and may result in low cardiac output syndrome that has been incriminated in early mortality and poor quality of life \[[@CR6], [@CR7]\].

For more than four decades, the Holy Grail in cardiac surgery has been focused in numerous cardioprotective strategies founded on well-reasoned pathophysiological mechanisms, namely hypothermic cardiac arrest with potassium-enriched solutions as well as ischemic, pharmacological and anaesthetic pre (and post) conditioning \[[@CR8]\]. Nowadays, the infusion of cold blood or crystalloid solutions through the aortic root or selectively into coronary arteries has become a standard of care to minimize myocardial injuries during open heart surgery \[[@CR9]\]. So far, novel strategies, such as remote or direct ischemic myocardial preconditioning have failed to provide convincing clinical results \[[@CR10]\].

Since its introduction in 1962 in the setting of ischemic heart diseases, the administration of glucose--insulin--potassium (GIK) has long been advocated to enhance myocardial protection in cardiac surgery \[[@CR11]\]. Experimental studies strongly support the cardioprotective effects of glucose--insulin--potassium (GIK) through metabolic modulation as well as antiapoptotic, anti-inflammatory and antioxidant effects \[[@CR12]\]. In patients undergoing CABGS, although GIK infusion has been associated with improved cardiac output and fewer episodes of atrial fibrillation \[[@CR13]\], data regarding clinical outcomes remain controversial and, patients with poor ventricular function who might benefit from a cardioprotective strategy have been excluded in most of these studies \[[@CR14]\]. Moreover, no study has been focused on the quantitative assessment of left ventricular (LV) function using transesophageal echocardiography (TEE).

Considering the potential cardioprotective effects of insulin, the current study was aimed to investigate the effects of GIK infusion on left ventricular systolic and diastolic function in moderate-to-high risk patients undergoing on-pump CABGS and receiving standard cardioprotective techniques.

Methods {#Sec2}
=======

This single-centre, randomized parallel group, superiority trial was approved by the institutional review board at the University Hospital of Geneva (CER: 08-095) and written consent was obtained from each eligible participant. From January 1, 2009 to December 31, 2013, adult patients scheduled for elective CABGS,---isolated or combined with aortic valve replacement (AVR)---, were screened and enrolled if they had a Bernstein-Parsonnet score higher than 7. Exclusion criteria consisted in poorly controlled diabetes mellitus, severe liver disease (Child--Pugh C stage), dementia or significant cerebrovascular disease as well as any contraindications for inserting a transoesophageal echocardiographic (TEE) probe. Results regarding clinical outcome and the occurrence of post-cardiotomy ventricular dysfunction (PCVD) in the whole study population (N = 212) have been reported previously \[[@CR15]\]. In the current investigation and, as pre-planned (ClinicalTrial.gov NCT00788242), we focused on a subset of patients who underwent CABG surgery with or without AVR (with severe aortic stenosis) and, in whom TEE examination was completed with good quality imaging.

Patients were randomized to receive coded solutions of saline (NaCl 0.9%, Placebo group) or GIK (human Actrapid, Novo Nordisk 20 IU and potassium chloride 10 mEq in 50 mL of 40% glucose, GIK group) over 60 min upon anaesthetic induction (Fig. [1](#Fig1){ref-type="fig"}). Randomization (1:1) was generated with a computer program and stratified based on Bernstein Parsonnet score ≤ 15 or \> 15, with permuted blocks of four patients. Study drug codes were stored in sealed envelopes and saline/GIK solutions were prepared by an anaesthesia nurse not involved in perioperative patient management nor in data recordings. Blood glucose concentration (BGC) were measured every 30 min and insulin and glucose (40% solution) were administered intravenously to maintain BGC between 4.5 and 10 mM/L throughout surgery. Anaesthesiologists, echocardiographers, surgeons and intensivists were blinded to group allocation as well as the two research assistants who separately collected pre- and intraoperative data as well as postoperative clinical outcome data.

Fig. 1Time line of the research protocol with study interventions and data collection. *GIK* glucose--insulin--potassium, *ICU* intensive care unit, *PGLS* peak global longitudinal strain, *POD* postoperative day, *TEE* transesophageal echocardiography

The standard anaesthetic technique consisted in intravenous administration of propofol and ketamine that was combined with intrathecal morphine analgesia (5--10 mcg/kg) to minimize the administration of opiates and to facilitate early extubation. Inhaled sevoflurane (1--1.5 MAC) was administered in all patients over at least 30 min before the start of CPB as a mean to enhance myocardial protection \[[@CR16]\]. All cardiac surgical procedures were performed via sternotomy, under normothermic nonpulsatile CPB with the circuit and membrane oxygenator primed with 1.5--2 L of fluids (1L Ringer-Acetate and 0.5--1 L of hydroxyethyl starch 6% 130/0.4). After aortic cross-clamping, cold blood cardioplegia was periodically infused in the aortic root to ensure myocardial protection and 250 mL of normothermic perfusate was given prior to aortic declamping.

Weaning from CPB was guided by TEE and hemodynamic measurements \[[@CR17]\]. Inotropes (dobutamine, epinephrine, milrinone) were initiated in the presence of new/worsening ventricular dysfunction and low MAP (\< 70 mmHg) that was not responsive to fluid loading and/or vasopressor therapy. Conversely, the decision to withdraw inotropic support was taken if the hemodynamic condition improved steadily.

The primary outcome variables were the left ventricular ejection fraction (LVEF) as measured by two- and three dimensional (2D and 3D) echocardiography as well as the transmitral flow propagation velocity (Vp). Secondary study endpoints included other TEE parameters, the occurrence of PCVD, any postoperative complications (modified Dindo--Clavien classification, grade ≥ 2) and peak troponin-I plasma concentrations.

Using a multiplane TEE probe with an iE33 ultrasound system (Philips Medical System, Eindhoven, Netherland), intraoperative imaging was performed at three time points, before drug infusion, 20 min after drug infusion and at the end of surgery (Fig. [1](#Fig1){ref-type="fig"}). Cine loops were obtained by two TEE experts from standard mid-esophageal four- and two-chamber (4C and 2C) views and transgastric mid-papillary short-axis views. All cine loops were stored on an external hard disc and used for evaluations if they corresponded to the appropriate standard views \[[@CR18]\]. The papillary muscles were included in the volumes or areas. In the mid-esophageal 4C and 2C views, the LV endocardial borders in end-diastole and end-systole were automatically detected using the preinstalled software based on a geometric model of the LV consisting of 20 circular or ellipsoid columns (biplane Simpson's method of disks). After manual adjustment of the endocardial border, the end-diastolic and end-systolic volume (ESV and EDV) were measured and the LVEF was calculated (LVEF = \[EDV − ESV\]/EDV). The transgastric mid-papillary short-axis view served to manually trace the end-diastolic area and end-systolic area (EDA and ESA) and to calculate the fractional area change (LVFAC = \[EDA − ESA\]/EDA). From M-mode recordings, the posterior wall thickness (PWT) was measured at end-diastole.

After acquiring a full volume scan of the left ventricle from 4 R-wave triggered sub-volumes, real-time 3D data sets were analysed with the QLAB 3D-advanced quantification software package to measure LV volume and compute 3D-LVEF. Using tissue Doppler imaging (TDI), early and late myocardial diastolic velocities (e′ and Am) were measured and the E/e′ ratios were calculated. To determine the transmitral flow propagation velocity (Vp), the color M-mode was used in the mid-esophageal 4-chamber view by adjusting the Nyquist limit and baseline shift. Speckle-tracking analysis was performed using the cardiac motion quantification software (CMQ-Advanced; Philips Healthcare, Eindhoven, Netherland) before drug administration and at the end of surgery. Two consecutive ECG-gated cardiac cycles were acquired on the three longitudinal apical views (4CH, 3CH and 2CH) at a frame rate of 40--80 Hz and stored digitally and, peak global longitudinal strain (PGLS) was calculated as the mean of all strain values from basal, mid-papillary and apical segments. Diastolic dysfunction was diagnosed and graded according to the American Society for Echocardiography (ASE) recommendations (normal, impaired relaxation, pseudo-normalization and restrictive pattern) \[[@CR19]\].

At least 30 patients per group are required to detect LVEF changes over 3 measurements in the Placebo group and in the GIK group resulting in a between-group difference of 5% (assuming a variance of 64 at each measurement, a correlation of 0.7 between the repeated measurements, a power of 0.8, and a type I error of 0.05). This power calculation is independent from the baseline value of LVEF.

Summary descriptive statistics are expressed as frequencies (and percentages, %), medians (and interquartile range, IQR 25--75%), means (and standard deviations, SD; 95% confidence intervals, CI) and risk ratios (RR and 95% confidence interval, 95% CI). Pearson's correlation coefficient was used to assess the inter- and intra-observer variability of the TEE measurements in randomly selected patients (n = 10). To analyze differences between the two groups, two-sided unpaired t tests, Wilcoxon rank-sum tests, or chi-squared tests were used where appropriate. Repeated-measures two-way analysis of variance (ANOVA) with Greenhouse-Geisser correction was used to estimate between and within group differences. Statistical tests were conducted using STATA 14 software (Stata Corp, College Station, TX, USA).

Results {#Sec3}
=======

From a total of 295 screened patients, 224 were randomized into GIK and Placebo groups (110 and 112, respectively). Among those undergoing CABG surgery or CABG surgery associated with AVR, 49 were allocated to the Placebo group and 66 to the GIK group (Fig. [2](#Fig2){ref-type="fig"}). After exclusion of cases with unavailability to perform TEE or poor quality imaging (N = 15), 100 patients remained for final analysis, 46 in the Placebo group and 54 in the GIK group.

Fig. 2Consolidated Standards of Reporting Trials flow diagram

As shown in Table [1](#Tab1){ref-type="table"}, baseline preoperative clinical and biological variables were well balanced in the two groups, except for a lower LVEF in the GIK group. Intraoperative surgical characteristics, blood glucose concentrations and supplemental administration of insulin and glucose did not differ between the two groups.

Table 1Characteristics of patients undergoing coronary artery bypass grafting and receiving Placebo or glucose--insulin potassium (GIK) infusionCharacteristicsPlaceboGIKp value(N = 46)(N = 54)Demographics Age, years^a^69.3 (11.0)71.8 (8.4)0.266^†^ Body mass index^a^26.4 (4.2)28.7 (4.6)0.021^†^ Sex, male40 (87.0)41 (75.9)0.161^‡^Comorbidities Bernstein-Parsonnet score^a^20.5 (8.8)21.8 (8.6)0.459^†^ Hypertension41 (89.1)53 (98.2)0.058^‡^ Pulmonary hypertension3 (6.5)7 (13.0)0.335^‡^ Hypercholesterolemia37 (80.4)51 (94.4)0.032^‡^ Diabetes mellitus18 (38.1)29 (53.7)0.146^‡^ Vascular disease20 (43.5)23 (42.6)0.929^‡^ Chronic obstructive pulmonary disease8 (17.4)9 (16.7)0.923^‡^ Heart failure NYHA III/IV15 (32.7)20 (37.0)0.679^‡^ Left ventricular ejection fraction^b^, %44 (4.5)41 (2.9)0.036^†^ Left ventricular wall thickness^b^, mm1.12 (0.20)1.15 (0.16)0.514^†^ Previous cardiac surgery8 (8.7)14 (13.0)0.541^‡^Chronic treatment Beta-blockers34 (74)35 (65)0.389^‡^ Calcium-channel antagonists9 (19.6)14 (25.9)0.633^‡^ ACEI/AII antagonists24 (52.2)25 (45.4)0.688^‡^ Diuretics22 (39.3)23 (42.6)0.688^‡^Blood parameters Hemoglobin, g/dL^a^11.8 (1.9)11.9 (2.4)0.811 Creatinine clearance, mL/min^a^80.3 (45.5)74.8 (30.5)0.477Surgical characteristics CABG with AVR16 (34.8)17 (31.5)0.726^‡^ Number of coronary grafts3 (1--5)3 (1--4)0.859 Aortic clamping time, min^a^74.1 (31.9)81.2 (38.1)0.323^†^ Fluids, mL^a^2927 (977)3330 (1810)0.180^†^ Blood transfusion31 (67.4)39 (72.2)0.599^‡^ Fresh frozen plasma15 (32.6)16 (29.6)0.748^‡^ Platelets8 (17.4)11 (20.4)0.705^‡^ Blood glucose (mMol/L)  Start of surgery^a^6.7 (1.5)7.3 (2.1)0.166^†^  Before bypass^a^7.6 (1.3)7.8 (3.0)0.680^†^  During bypass^a^8.0 (1.8)7.6 (2.8)0.493^†^  End of surgery^a^7.9 (1.2)7.3 (1.9)0.101^†^ Supplemental insulin10 (21.4)19 (35.2)0.140^‡^ Supplemental glucose infusion1 (2.2)5 (9.3)0.214^‡^Data given as number of patients (percentage) unless otherwise indicated*ACEI* angiotensin converting enzyme inhibitors, *AII* angiotensin II, *AVR* aortic valve replacement, *CABG* coronary artery bypass grafting, *CPB* cardiopulmonary bypass, *LVEF* left ventricular ejection fractionChi-squared tests were used for statistical tests unless otherwise indicated; ^†^Student t test; ^‡^Fisher exact test^a^Data given as mean (standard deviation) or median (range)^b^Transthoracic echocardiography performed the day before surgery

Intra- and interobserver variabilities were good to excellent for 2D-LVEF, 3D-LVEF and PGLS and, intermediate values were achieved for Vp as assessed by Pearson coefficients (Table [2](#Tab2){ref-type="table"}).

Table 2Interobserver and intraobserver variability for measurements of transoesophageal echocardiographic dataMeasurementsInterobserver correlation coefficient95% confidence intervalIntraobserver correlation coefficient95% confidence interval2D-LVEF0.9100.742--0.9660.9030.802--0.9553D-LVEF0.8320.621--0.9460.8700.615--0.988PGLS0.8760.579--0.9280.8790.661--0.922Vp0.7620.538--0.9550.8110.507--0.954*2D-LVEF* two-dimensional left ventricular ejection fraction, *3D-LVEF* three-dimensional left ventricular ejection fraction, *PGLS* peak global longitudinal strain, *Vp* transmitral flow propagation velocity

At preoperative baseline, LVFAC, 2D-LVEF, 3D-LVEF and Vp were slightly lower in the GIK group compared with the Placebo group (Table [3](#Tab3){ref-type="table"}).

Table 3Echocardiographic parameters in patients undergoing coronary artery bypass grafting and receiving Placebo or glucose--insulin potassium (GIK) infusionParameterStart surgeryAfter GIKEnd surgeryp-valuePreload End diastolic area (cm^2^)  All patients13.6 (2.7)13.1 (2.7)12.9 (3.1)0.002  Placebo group13.7 (2.3)13.2 (2.4)13.0 (3.0)\< 0.036  GIK group13.6 (3.0)13.1 (2.9)12.8 (3.3)\< 0.038Effect modification by GIK0.953Systolic function LV FAC (%)  All patients43.2 (8.7)42.8 (9.9)41.8 (9.6)0.278  Placebo group46.2 (7.4)41.8 (8.8)39.4 (9.8)\< 0.001  GIK group40.6 (9.0)43.7 (10.8)43.9 (9.1)0.006Effect modification by GIK\< 0.001 3D-LVEF (%)  All patients44.2 (6.9)43.9 (6.4)42.6 (7.0)0.007  Placebo group46.8 (6.6)44.2 (6.7)41.1 (7.5)\< 0.001  GIK group42.1 (6.4)43.7 (6.2)43.8 (5.7)0.017Effect modification by GIK\< 0.001 2D-LVEF (%)  All patients41.4 (6.0)40.9 (6.2)40.7 (7.2)0.315  Placebo group42.5 (5.3)40.4 (6.0)39.3 (8.3)\< 0.001  GIK group40.5 (6.4)41.3 (6.4)41.9 (5.9)0.093Effect modification by GIK\< 0.001 PGLS (%)  All patients− 12.3 (2.6)--− 11.2 (2.4)0.002  Placebo group− 13.1 (2.2)--− 11.3 (2.7)\< 0.001  GIK group− 11.5 (2.5)--− 11.2 (2.1)0.369Effect modification by GIK\< 0.007 LV systolic strain rate (s^−1^)  All patients− 1.03 (0.28)--− 0.99 (0.24)0.124  Placebo group− 1.12 (0.28)--− 1.01 (0.26)0.007  GIK group− 0.94 (0.26)--− 0.97 (0.23)0.396Effect modification by GIK0.008Diastolic function Transmitral E/A ratio  All patients1.19 (0.65)1.15 (0.50)1.19 (0.49)0.593  Placebo group1.24 (0.62)1.11 (0.46)1.00 (0.48)0.001  GIK group1.14 (0.67)1.18 (0.54)1.34 (0.46)0.021Effect modification by GIK\< 0.001 Isovolemic relaxation time (ms)  All patients82.2 (37.7)84.9 (35.7)85.0 (33.7)0.361  Placebo group88.5 (35.5)88.8 (36.5)86.9 (34.7)0.729  GIK group76.9 (39.0)81.6 (35.0)83.4 (33.1)0.140Effect modification by GIK0.218 Pulmonary venous S/D ratio  All patients1.34 (0.55)1.38 (0.52)1.42 (0.47)0.025  Placebo group1.26 (0.49)1.31 (0.52)1.35 (0.48)0.311  GIK group1.42 (0.62)1.44 (0.52)1.58 (0.45)0.058Effect modification by GIK0.535 Early lateral velocity (cm/s)  All patients9.7 (3.0)9.5 (2.9)8.2 (2.8)\< 0.001  Placebo group10.1 (3.0)9.4 (2.7)7.0 (2.3)\< 0.001  GIK group9.4 (3.0)9.5 (3.1)9.2 (2.8)0.660Effect modification by GIK\< 0.001 E/e´ ratio  All patients7.1 (3.3)7.1 (2.9)7.7 (2.8)0.037  Placebo group6.8 (2.1)6.8 (2.0)8.2 (2.6)\< 0.001  GIK group7.3 (4.0)7.4 (3.5)7.1 (2.8)0.735Effect modification by GIK0.001 Flow propagation velocity (cm/s)  All patients39.3 (8.8)39.6 (6.1)39.2 (7.9)0.793  Placebo group43.9 (7.4)39.2 (5.7)34.5 (6.9)\< 0.001  GIK group35.3 (8.0)39.9 (6.4)43.2 (6.3)\< 0.001Effect modification by GIK\< 0.001Data given as mean (standard deviation)Repeated-measures two-way analysis of variance (ANOVA) with Greenhouse-Geisser correction was used to estimate trend differences between and within group differences*LV FAC* left ventricular fractional area change, *3D-LVEF* three-dimensional left ventricular ejection fraction, *2D-LVEF* two-dimensional left ventricular ejection fraction, *PGLS* peak global longitudinal strain

The administration of GIK was associated with strong interaction effects on LVFAC, 2D-LVEF, 3D-LVEF and Vp throughout the study periods (p \< 0.001 for all four TEE parameters; Table [3](#Tab3){ref-type="table"}; Fig. [3](#Fig3){ref-type="fig"} and [Appendix](#Sec5){ref-type="sec"}). Before starting CPB, GIK infusion was associated with a mean increase of 7.7% in LVFAC (95% CI 2.6 to 12.9%), 2.0% in 2D-LVEF (95% CI − 0.5 to 4.5%), 3.8% in 3D-LVEF (95% CI 1.6 to 5.9%), and 13% in Vp (95% CI 9.4 to 16.2%). After weaning from CPB and compared to baseline, LVFAC increased by 8.0% (95% CI 3.4 to 12.7%), 2D-LVEF by 3.5% (95% CI − 0.2 to 7.1%), 3D-LVEF by 4.0% (95% CI 0.6 to 7.4%), and Vp by 22.2% (95% CI 16.0 to 28.4%), in the GIK group. In contrast, patients in the Placebo group exhibited reductions in LVFAC (mean difference \[MD\] − 14.6%, 95% CI − 19.2 to − 10.0%), in 2D-LVEF (MD − 7.5%, 95% CI − 11.6 to − 3.4%), in 3D-LVEF (MD − 12.0%, 95% CI − 15.2 to − 8.8%), and in Vp (MD − 21.3%, 95% CI − 25.7 to − 16.9%).

Fig. 3Intraoperative changes in echocardiographic parameters occurring in patients undergoing CABG surgery. Data from 100 patients with complete high quality TEE exams (Placebo group N = 46; GIK group N = 54). \*Post-drug compared with baseline, p \< 0.05; ^\#^end of surgery compared with baseline, p \< 0.05; ^†^GIK compared with Placebo, p \< 0.05

The administration of GIK was also associated with strong interaction effects on PGLS, LV systolic strain rate, and the E/e′ ratio (p = 0.007, p = 0.008, respectively p = 0.001). In the two groups, changes in TEE parameters did not differ among patients undergoing isolated CABGS compared with those undergoing CABGS combined with AVR.

Regarding clinical outcome, GIK pretreatment was associated with a reduction in respiratory complications (RR 0.62, 95% CI 0.44 to 0.88) and in PCVD (RR 0.25, 95% CI 0.09 to 0.63) along with lesser requirements for norepinephrine (30 \[55.6%\] vs. 36 \[78.3%\], in the Placebo group, p = 0.017), dobutamine (18 \[33.3%\] vs. 30 \[65.2%\] in the Placebo group, p = 0.001), or a combination of at least two inotropes (17 \[31.5%\] vs. 28 \[60.9%\] in the Placebo group, p = 0.003). In-hospital mortality, the incidence of cardiovascular complications and renal dysfunction, as well as peak levels of cardiac troponin-I did not differ between the two groups (Table [5](#Tab5){ref-type="table"} in [Appendix](#Sec5){ref-type="sec"}).

Discussion {#Sec4}
==========

The optimal protection of the myocardium during on-pump cardiac surgery remains a challenge and it markedly impacts clinical outcome after myocardial revascularization and valvular surgery \[[@CR7], [@CR21]\]. In this RCT including moderate-to-high risk patients undergoing isolated or combined CABGS, GIK infusion resulted in immediate improvement in systolic and diastolic LV function and it prevented the impairment of LV function that was observed early after weaning from CPB in patients receiving the standard cardioprotective technique. Moreover, GIK pre-treatment was associated with lesser need for cardiovascular drug support, fewer respiratory complications and shorter ICU length of stay.

In previous clinical trials conducted in CABGS, patients with poor ventricular function were often excluded and therefore, functional benefit could not be demonstrated given the lower patient risk characteristics \[[@CR14]\]. In the present trial, the moderate-to-elevated risk profile was mainly related to advanced age (60% older than 70 years) and a high prevalence of comorbidities (hypertension in 93% of patients, vascular disease in 43%, heart failure in 35%, diabetes mellitus in 28% and aortic valve stenosis in 33%). With a mean Parsonnet score of 21, the expected mortality was 5.5% \[[@CR22]\]. The lower observed mortality (4.0%) was partly attributed to standardization of perioperative anaesthetic and surgical processes including the goal-directed approach based on TEE and hemodynamic monitoring \[[@CR23]\].

To assess the intraoperative changes in LV function, we used 2D and 3D-TEE as well as speckle tracking imaging. Some limitations of standard 2D-imaging (e.g., geometric assumptions, foreshortenings and difficulties in proper delineation of the endocardial LV borders) were partly overcome by 3D echocardiography that has demonstrated excellent agreement with magnetic resonance imaging, the reference method for assessing LV function \[[@CR24], [@CR25]\]. Analysis of myocardial deformation based on velocity gradients measured by displacement of speckles from 2D images is another method to quantify longitudinal LV shortening that has been shown particularly valuable in patients with heart failure \[[@CR26]\].

During the pre-ischemic period, TEE indicators of systolic and diastolic function (2D-, 3D-LVEF and Vp) slightly decreased in the Placebo group as a result of the cardio-depressive effects of anesthetic agents \[[@CR27], [@CR28]\] whereas these parameters remained unchanged or increased after the infusion of GIK. In brain death-induced heart failure, GIK infusion has been shown to increase LVEF as much as moderate doses of dobutamine while avoiding tachyarrhythmias and arterial hypotension \[[@CR29]\]. Likewise in patients with severe coronary artery disease, GIK infusion at a similar dosage has been shown to increase the ischemic threshold and LVEF while improving exercise tolerance and correcting stress-induced LV dysfunction \[[@CR30], [@CR31]\].

In the present protocol, the administration of insulin at a rate of 4 to 6 mU/kg/min was expected to achieve plasma insulin concentrations in the range of 3 to 4 nmol/L (equivalent to 0.4 to 0.5 IU/L), these levels being necessary to provide short-term enhancement of ventricular performances and cardioprotective effects \[[@CR32]\].

Several mechanisms are responsible for GIK-induced enhancement of ventricular contractility at lesser oxygen demand. First, in isolated cardiac muscle preparations, insulin exerts concentration-dependent positive inotropic effects after coupling to specific membrane receptors and subsequent stimulation of calcium ATPase activity, sodium/calcium exchange activity as well as calcium current in L-type channel \[[@CR33]\]. Second, sensitization and increase in beta-1 adrenergic receptors may further enhance myoplasmic calcium availability by increasing cyclic adenosine monophosphate substrates \[[@CR34], [@CR35]\]. Third, GIK has been shown to suppress the surgically-induced inflammatory response, as reflected by reduced levels of C-reactive protein, tumor necrosis factor-alpha and interleukin-6 that are implicated in cardiac contractile dysfunction \[[@CR36]\]. Finally, in GIK treated hearts, the increased glucose uptake coupled with decreased free fatty acid (FFA) uptake, results in a shift from FFA to glucose aerobic metabolism and more efficient oxygen utilization, with larger amounts of ATP being generated per oxygen mole and directly available for excitation--contraction coupling within the cardiomyocytes \[[@CR37]\]. Contrasting with the immediate response to beta-adrenergic receptor agonists, the maximal positive inotropic effects has been shown to occur 20 to 40 min after GIK infusion and this delayed response lend support to a predominant metabolic effect of the GIK \[[@CR38]\].

After weaning from CPB and compared with pre-bypass conditions, the Placebo group exhibited a significant decline in both LV systolic and diastolic function that required the administration of inotropes in two-third of patients. Although inotropic support may transiently enhance post-ischemic recovery and facilitate weaning from CPB, it has been identified as a strong predictor of increased mortality and cardiovascular complications in cardiac surgery, possibly resulting from increased oxygen consumption, exhaustion of energetic substrates and beta-adrenergic desensitization within the myocardium \[[@CR6]\].

In contrast, in GIK pretreated patients, echocardiographic markers of LV systolic function were well preserved compared with preoperative baseline, LV diastolic function was even improved and therefore, only a third of these patients required inotropic support following CPB. Mitigation of the contractile dysfunction with GIK pretreatment may result from optimization of cardiac metabolism and promotion of cardiomyocyte survival pathways before the onset of myocardial ischemia \[[@CR12], [@CR35]\]. In fasted animals, the oxidation of glucose, lactate and pyruvate contributes to less than 5% of myocardial energy production and has been associated with greater vulnerability to ischemic myocardial damages due to uncoupling of mitochondrial oxidative phosphorylation and energy dissipation \[[@CR39]\]. In contrast, GIK infusion promotes a fed-liked state by altering gene expression and enzymes activities resulting in enhanced glucose uptake and glycogen synthesis with increased provision of high-energy substrates (ATP and creatinine phosphate) to sustain short period of myocardial ischemia. Indeed, experimental studies have reported an association between high pre-ischemic glycogen content and improved functional recovery from ischemia \[[@CR36], [@CR40]\].

Besides this glucose-dependent mechanism, insulin further protects the cardiomyocytes by activation of the phosphoinositide 3-kinase/protein kinase B (PI3K/Akt) pathway that regulates various signaling intracellular targets (e.g., endothelial nitric oxide synthase, mammalian target of rapamycine, forkhead transcription factors) and therefore minimizes apoptosis triggered by the ischemic insult \[[@CR12], [@CR41]\].

This study has some limitations. First, although both groups presented similar comorbidities and operative risk score, baseline GIK-treated patients presented lower LVEF than in the Placebo group, making them more sensitive to subsequent functional improvement. Second, TEE assessment was exclusively focused on the LV, using load-dependent indices of LV systolic function and mitral flow propagation velocity, a load-independent surrogate of LV relaxation. These investigation tools could also be applied to the RV which may benefit (or not) from GIK infusion. Third, this substudy was not designed nor powered to evaluate meaningful clinical outcomes. Hence, the observed improvement in LV function and reduced need for inotropes did not translate into reduced postoperative cardiac mortality and morbidity, except a reduced occurrence of pulmonary complications that was explained by easier weaning from the ventilator consequent to improved LV function. Interestingly, Duncan et al. recently reported that intraoperative maintenance of normoglycemia with a fixed high-dose insulin and variable glucose adjustment was associated with reduced 30-day mortality and morbidity after cardiac surgery \[[@CR42]\].

In conclusion, we observed that the addition of GIK therapy to standard cardioprotective techniques in moderate-to-high risk patients with ischemic heart disease resulted in better preservation of LV systolic and diastolic function in the early period following separation from cardiopulmonary bypass. Further studies are required to warrant the long term clinical impact of improved functional recovery of the myocardium early after cardiac surgery.

Appendix {#Sec5}
========

See Fig. [4](#Fig4){ref-type="fig"} and Tables [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}.

Fig. 4Individual changes in fractional area changes (FAC) after drug infusion (Placebo or GIK) and after weaning from cardio-pulmonary bypass

Table 4Grading of left ventricular diastolic function by echocardiographyStart of surgeryAfter GIK/placeboEnd of surgeryNormal Placebo (N = 46)4 (8.7)5 (8.7)2 (4.3) GIK (N = 54)5 (9.2)10 (18.4)8 (14.8)Grade I impaired relaxation Placebo21 (45.5)20 (43.5)18 (43.9) GIK23 (42.6)27 (50.0)27 (50.0)Grade II pseudo-normalization Placebo15 (32.6)16 (34.8)16 (34.8) GIK18 (33.3)14 (25.9)14 (25.9)Grade III restrictive pattern Placebo6 (13.0)5 (10.9)10 (21.7) GIK8 (14.8)3 (5.5)5 (9.3)Data given as number of patients (percentage)Based on Nagueh et al. \[[@CR20]\]

Table 5Clinical outcomes of patients undergoing coronary artery bypass grafting and receiving Placebo or glucose--insulin potassium infusionOutcomePlaceboGIKRR(95% CI)p-value(N = 46)(N = 54)Mortality5 (10.9)1 (1.9)0.17(0.02; 1.41)0.092\*Cardiovascular complications^c^25 (54.4)25 (46.3)0.85(0.58; 1.23)0.422 Atrial fibrillation18 (39.1)17 (31.5)0.80(0.47; 1.37)0.424 New/worsening heart failure9 (19.6)4 (7.4)0.38(0.12; 1.15)0.083\* Myocardial infarct8 (17.4)8 (14.8)0.85(0.35; 2.10)0.726 Stroke5 (10.9)1 (1.9)0.17(0.02; 1.41)0.092\*Pulmonary complications^d^33 (71.7)24 (44.4)0.62(0.44; 0.88)0.006 Atelectasis20 (43.5)10 (18.5)0.43(0.22; 0.82)0.007 Pneumonia5 (9.3)5 (10.9)0.85(0.26; 2.76)0.789 Ventilation \> 24 h30 (65.2)17 (31.5)0.48(0.31; 0.75)0.001Renal dysfunction^e^14 (30.4)10 (18.5)0.61(0.30; 1.24)0.164Troponin I 16--24 h post-surgery, ng/mL^a^4.1 (2.5; 7.9)3.5 (1.9; 7.0)0.59^b^(− 0.78; 1.86)0.354^\#^Data given as number (percentage) unless otherwise indicated. Chi-squared tests were used for statistical tests unless otherwise indicated*RR* risk ratio, *ICU* intensive care unit\* Fisher exact test^\#^Wilcoxon rank sum test^a^Data given as median (range)^b^Median difference^c^Composite including new or worsening LV failure, myocardial infarct, atrial fibrillation, and stroke^d^Composite including atelectasis, pneumonia, and mechanical ventilation \> 24 h^e^Increase in estimated glomerular filtration rate \> 25%
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